Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.

Reduced sexual drive may be linked to male breast cancer, while anti-estrogenic factors might lower the risk.

Finasteride, a hair loss drug, may cause sexual dysfunction and depression, but these effects are usually temporary and the drug is generally safe. More research is needed.

5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.

Lipocalin-Type Prostaglandin D2 Synthase (L-PGDS) is a protein that plays many roles in the body, including sleep regulation, pain management, food intake, and protection against harmful substances. It also affects fat metabolism, glucose intolerance, cell maturation, and is involved in various diseases like diabetes, cancer, and arthritis. It can influence sex organ development and embryonic cell differentiation, and its levels can be used as a diagnostic marker for certain conditions.

PCOS increases sexual pain and distress in infertile Iranian women.

Some people experience lasting sexual, psychological, and sleep problems after using finasteride or SSRI antidepressants, possibly due to similar underlying causes.

Hair loss in alopecia areata can negatively affect sexual quality of life.

Woodhouse-Sakati syndrome often causes sexual development issues, hair loss, learning disabilities, deafness, muscle contractions, limb pain, and diabetes.

Shrunken heads retain some facial features and hair characteristics, allowing for limited individual identification.

Polycystic Ovary Syndrome (PCOS) is common in women with conditions like anovulation, hirsutism, hair loss, and type 2 diabetes, and it can lead to health risks like heart disease, obesity, insulin resistance, and depression. Non-Classic Congenital Adrenal Hyperplasia (NC-CAH) is also discussed.

New treatments for low male hormones improved sexual function and mood but had unclear risks, especially for older men.

Red ginseng oil improves urinary symptoms and some sexual functions in men safely.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

Finasteride can reduce prostate cancer risk but may delay diagnosis and cause sexual side effects.

Children's hair grows in different types from before birth through puberty, with growth rates and characteristics varying by age, sex, and race.

Chinese domestic goats have unique genetic traits due to domestication and geographic isolation.

Male hormones cause different growth in identical human hair follicles due to their unique epigenetic characteristics.

Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.

RSPO1 mutations in certain patients lead to skin cells that don't develop properly and are more likely to become invasive, increasing the risk of skin cancer.

Testosterone replacement therapy helps manage deficiency and has various methods, but requires careful monitoring to avoid side effects.

Many young women with breast cancer experience poor quality of life, especially in sexual health and hair loss, but future outlook improves over time.

Hormone therapy for trans individuals is effective and generally safe in the short term.

Rare adrenal cancers that secrete androgens or estrogens have a poor prognosis and are treated primarily with surgery.

Androgens affect the function and health of the endometrium.

Older age, obesity, hirsutism, and having children increase metabolic risk in women with PCOS.

Rasayana therapy can enhance female reproductive health at different life stages.

Gender identity can be more diverse than just male or female.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.